Vicuron Pharmaceuticals Announces Pricing of $70.8 Million Public Offering
September 30 2004 - 2:00AM
PR Newswire (US)
Vicuron Pharmaceuticals Announces Pricing of $70.8 Million Public
Offering KING OF PRUSSIA, Pa., Sept. 30 /PRNewswire-FirstCall/ --
Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato), today
announced that it has priced a public offering of 4,800,000 shares
of its common stock at $14.75 per share, for a total offering
amount of approximately $70.8 million. Vicuron has granted the
underwriter an option, exercisable for 30 days, to purchase up to
720,000 additional shares of its newly issued common stock to cover
over-allotments, if any. Morgan Stanley is acting as the sole
underwriter of the offering. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
any of these securities. The offering is being made solely by means
of a prospectus dated March 15, 2004 and the accompanying
prospectus supplement dated September 29, 2004. There shall not be
any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state. Copies
of the prospectus and prospectus supplement relating to the public
offering may be obtained from Morgan Stanley, Attention: Prospectus
Department, 1585 Broadway, New York, New York, 10036, telephone
212-761-6775. About Vicuron Vicuron Pharmaceuticals is a
biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing vital medicine for seriously ill
patients. Forward-Looking Statements This news release contains
forward-looking statements that predict or describe future events
or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that the
above-mentioned public offering may be delayed or cancelled, that
clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug
application or any amendment to a new drug application might be
delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that a third party may not be willing to license
our product candidates on terms acceptable to us or at all, that
competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively,
that a sales force may not be developed as contemplated and that
one or more of Vicuron's product candidates may not be
commercialized successfully. The reports that Vicuron files with
the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is
subject. Because of those risks, Vicuron's actual results,
performance or achievements may differ materially from the results,
performance or achievements contemplated by its forward-looking
statement. The information set forth in this news release
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release. DATASOURCE:
Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of
Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or Hala Bashir
of WeissComm Partners, +1-212-204-2080, or ; or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for Vicuron
Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright